Member Info for Astro

Https://www.linkedin.com/pulse/last-time-copper-officially-declared-structural-deficit-sam-hosack-x4w2f?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

This is a deep dive by Sam Hosack published 26 May 2026 Sam Hosack is Managing Director and CEO of Prospect Resources Limited (ASX: PSC), a copper exploration and development company with its flagship Mumbezhi Copper Project in north-western Zambia. This article represents his personal views and does not constitute investment advice. Prospect Resources is subject to ASX continuous disclosure obligations.

The inter partes hearing of the injunction application has now been scheduled for 10 September 2025, when the Company will have the opportunity to present all relevant facts and circumstances with the aim to secure ongoing injunctive relief after which the case can then proceed to the breach aspect of Arc's claim against MM and ZAMEX. Good timing by ARCM, I think Shonga will be putting manners on a few.

‘In addition to the deep drilling programme planned, the placing proceeds ..... may be applied to increase the Company's stake in the Company's Zamsort asset, subject to negotiations and commercial agreement’

04 Mar 2021 Appointment of Mr Gabriele Marco

https://find-and-update.company-information.service.gov.uk/company/12647178/filing-history

Learn About Tiziana Life Sciences (NASDAQ: TLSA) in Exclusive Zoom Presentation

Wednesday, February 24 at 21:15 pm GMT

Join Kunwar Shailubhai, CEO of Tiziana Life Sciences (NASDAQ: TLSA), to learn about the company’s targeted therapeutics being developed to transform treatment of liver diseases, inflammatory diseases, and cancer using proprietary oral, nasal, and inhaled formulation technologies.

Call information:

Topic: RedChip TLSA Group Call 24 Feb. 2021
Time: Wednesday, Feb 24, 2021 at 4:15 pm ET / 1:15 pm PT

Join Zoom Meeting
zoom.us/j/94492954348

Meeting ID: 944 9295 4348

mcap is 38 billion. They're 600x bigger than Arcm. They're not here for a small portion. They don't need Arcm IMO

Recap: from July 2020 6mins 30secs Dr Kunwar Shailubhai speaks to Proactive London's Andrew Scott talks about R&D strategy/J.V's, worth a full listen. https://youtu.be/tlM2FeObIUo

Tiziana Life Sciences PLC (TLSA) Rating: Buy
Raghuram Selvaraju, January 19, 2021
H.C.WAINWRIGHT&CO gives TLSA a buy rating and price target of $11
https://ir.tizianalifesciences.com/static-files/e6006275-cfa2-455a-8cc7-3221a7ea6883

Video clip by from JPMorgan conference recently, Shalibu Kunwar says "completely safe" a must watch

https://twitter.com/astrobrook/status/1352119103100772353?s=20

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Tiziana Life Sciences, with a price target of $11.00. https://www.markets.co/analysts-offer-insights-on-healthcare-companies-tiziana-life-sciences-nasdaq-tlsa-acceleron-pharma-nasdaq-xlrn-and-igm-biosciences-nasdaq-igms/291164/

A very good interview with the CEO GC by Bloomberg 2 months ago, he talks about the benefits of Foralumab and the gateway to it’s uses: ARDS, MERS, Progressive multiple sclerosis, Type 1 diabetes, Rheumatoid arthritis, Crohn’s & Alzheimer's disease. https://youtu.be/mdWbwt0utXg

US investors flock to UK biotech as sector delivers strong outperformance in a turbulent 2020

11 JAN 21 PRESS RELEASE
https://www.bioindustry.org/news-listing/us-investors-flock-to-uk-biotech-as-sector-delivers-strong-outperformance-in-a-turbulent-2020.html?utm_source=linkedin&utm_medium=organicsocial&utm_term=&utm_content=88e7a9d7-cf4b-4865-9a5c-c47e1d1be965&utm_campaign=

Foralumab is not a one trick pony, I believe it will set the stage re pipeline: MS, Crohn’s, Alzheimer’s, Covid, method delivery: nasally, orally and inhalation all patented. Also usable in combination therapy: TLZ-501, dexamethasone and remdesivir etc

Vascular, yes the more you listen/watch it the more you learn, very informative, the lungs are the vital point of a covid attack, very much looking forward to the top line data in conjunction with main market move this week. Have a good weekend all.

FORALUMAB will work independently on any covid variant, Brazil trial top line data results imminent, Dr Howard Weiner explains the workings in layman's terms, very good listen for any investor. https://www.proactiveinvestors.co.uk/companies/news/937552/tiziana-life-sciences-hails-positive-feedback-in-its-first-ever-covid-19-clinical-trial-937552.html

https://twitter.com/ArcMinerals/status/1321770639645122560?s=20

Exec Chairman Nick von Schirnding: "I am very encouraged by developments at Fwiji - not only is this the first time we have found this area .........................

RENX done the exactly what we're planning on doing from the months March - July.. so why are we struggling to complete?

https://www.lse.co.uk/news/RENX/renalytix-confirms-plans-for-demerger-of-fractaldx-ia9lcdlkj1zlxf7.html

P.S I forgot to add the superior bit :-)

If you could get your money back for the tool in the first year, that would be a result in itself, so If you used the current annual revenue for Precision Oncology by Exact Science approx $500m that would be more like fair value for Stem.

Looking at Exact Science latest figures, Precision Oncology revenue was $128.4 million for the three-month period ended March 31, 2020, so x4 would = £513.6 million approx per annum, expenses would have to be deducted of course to get the net profit, but looking at the pre existing tool Oncotype DX earning over half a billion in revenue certainly makes Stem a steal @ 300 mil if not a giveaway? https://www.prnewswire.com/news-releases/exact-sciences-announces-first-quarter-2020-results-301054271.html